what is bronchitis
Info about bronchitis coughing => bronchitis cures => Topic started by: glennaguilar on September 16, 2016, 07:51:03 am
-
Bronchitis Symptom - Understanding When Bronchitis Treatment is Necessary
Many patients who suffer from respiratory conditions are diagnosed with bronchitis. Bronchitis is a very common respiratory illness and it can occur in anyone, regardless of age. However, bronchitis has a higher incidence in smokers, people with respiratory insufficiency and people with weak immune system. The problem with bronchitis is that it generates symptoms that have an unspecific character. The symptoms of bronchitis are also characteristic to other respiratory illnesses and in many cases they can be misleading in establishing the appropriate diagnose. ;)
You are suffering from viral forms of acute bronchitis, it is advised to rest properly, drink plenty of fluids (especially if you have fever) and use a vaporizer or humidifier in your bedroom (dry air can cause throat soreness and difficulty breathing). Avoid using cough suppressants! They prevent the elimination of mucus and can cause serious complications. You can help in decongesting the airways clogged with mucus by taking a hot shower or bath.
Bronchitis treatments for chronic forms of the illness often include bronchodilators such as albuterol and ipratropium. These are inhaled medicines that eliminate the excess mucus responsible for obstruction of the respiratory tract and shortness of breathing. Bronchitis treatments can also include steroids for strengthening the body's defenses against bacteria and viruses. It is only if you find some usage for the matter described here on Bronchitis cough (http://rubennorris8.createmybb3.com/thread-85.html) that we will feel the efforts put in writing on Bronchitis Common fruitful. So make good usage of it! :o.
The symptoms of bronchitis persist for more than 2 days, it is strongly recommended to see a doctor. He will perform a physical examination or laboratory tests in order to reveal the nature of the illness. The doctor will only prescribe a specific bronchitis treatment if the illness is serious and caused by infection with bacteria. We do hope that you find the information here something worth recommending others to read and think about once you complete reading all there is about Symptoms Bronchitis.
Although they aren't very safe, long-term bronchitis treatments with antibiotics are prescribed for overcoming chronic forms of the illness. The problem with bronchitis treatments that involve the use of antibiotics is that they can weaken the organism in time, making it more vulnerable to other infections. Despite their efficiency in fighting malign bacteria, bronchitis treatments with antibiotics also destroy internal benign bacteria that are part of the immune system. Looking for something logical on Bronchitis, we stumbled on the information provided here. Look out for anything illogical here.
Even if the illness is correctly diagnosed, prescribing the best bronchitis treatment is a challenging task for doctors. Antibiotics are often part of bronchitis treatments. However, if bronchitis is caused by viruses, it is considered that bronchitis treatments with antibiotics are ineffective in overcoming the illness. In some viral forms of acute bronchitis, medical treatment isn't required at all, as the illness clears on itself in a few weeks. Even if the illness is caused by bacteria, bronchitis treatments with antibiotics can cause a lot of harm to the organism if they are administered continuously. What we have written here about Bronchitis Treatments can be considered to be a unique composition on Bronchitis Treatments. Let's hope you appreciate it being unique.
The fluoroquinolones are a relatively new group of antibiotics. Fluoroquinolones were first introduced in 1986, but they are really modified quinolones, a class of antibiotics, whose accidental discovery occurred in the early 1960.
Gastrointestinal Effects
The most common adverse events experienced with fluoroquinolone administration are gastrointestinal (nausea, vomiting, diarrhea, constipation, and abdominal pain), which occur in 1 to 5% of patients. CNS effects. Headache, dizziness, and drowsiness have been reported with all fluoroquinolones. Insomnia was reported in 3-7% of patients with ofloxacin. Severe CNS effects, including seizures, have been reported in patients receiving trovafloxacin. Seizures may develop within 3 to 4 days of therapy but resolve with drug discontinuation. Although seizures are infrequent, fluoroquinolones should be avoided in patients with a history of convulsion, cerebral trauma, or anoxia. No seizures have been reported with levofloxacin, moxifloxacin, gatifloxacin, and gemifloxacin. With the older non-fluorinated quinolones neurotoxic symptoms such as dizziness occurred in about 50% of the patients. Phototoxicity. Exposure to ultraviolet A rays from direct or indirect sunlight should be avoided during treatment and several days (5 days with sparfloxacin) after the use of the drug. The degree of phototoxic potential of fluoroquinolones is as follows: lomefloxacin > sparfloxacin > ciprofloxacin > norfloxacin = ofloxacin = levofloxacin = gatifloxacin = moxifloxacin. Musculoskeletal effects. Concern about the development of musculoskeletal effects, evident in animal studies, has led to the contraindication of fluoroquinolones for routine use in children and in women who are pregnant or lactating. Tendon damage (tendinitis and tendon rupture). Although fluoroquinolone-related tendinitis generally resolves within one week of discontinuation of therapy, spontaneous ruptures have been reported as long as nine months after cessation of fluoroquinolone use. Potential risk factors for tendinopathy include age >50 years, male gender, and concomitant use of corticosteroids. Hepatoxicity. Trovafloxacin use has been associated with rare liver damage, which prompted the withdrawal of the oral preparations from the U.S. market. However, the IV preparation is still available for treatment of infections so serious that the benefits outweigh the risks. Cardiovascular effects. The newer quinolones have been found to produce additional toxicities to the heart that were not found with the older compounds. Evidence suggests that sparfloxacin and grepafloxacin may have the most cardiotoxic potential. Hypoglycemia/Hyperglycemia. Recently, rare cases of hypoglycemia have been reported with gatifloxacin and ciprofloxacin in patients also receiving oral diabetic medications, primarily sulfonylureas. Although hypoglycemia has been reported with other fluoroquinolones (levofloxacin and moxifloxacin), the effects have been mild. Hypersensitivity. Hypersensitivity reactions occur only occasionally during quinolone therapy and are generally mild to moderate in severity, and usually resolve after treatment is stopped.
All of the fluoroquinolones are effective in treating urinary tract infections caused by susceptible organisms. They are the first-line treatment of acute uncomplicated cystitis in patients who cannot tolerate sulfonamides or TMP, who live in geographic areas with known resistance > 10% to 20% to TMP-SMX, or who have risk factors for such resistance.
First Generation
The first-generation agents include cinoxacin and nalidixic acid, which are the oldest and least often used quinolones. These drugs had poor systemic distribution and limited activity and were used primarily for gram-negative urinary tract infections. Cinoxacin and nalidixic acid require more frequent dosing than the newer quinolones, and they are more susceptible to the development of bacterial resistance.
Fourth Generation
The fourth-generation fluoroquinolones add significant antimicrobial activity against anaerobes while maintaining the gram-positive and gram-negative activity of the third-generation drugs. They also retain activity against Pseudomonas species comparable to that of ciprofloxacin. The fourth-generation fluoroquinolones include trovafloxacin (Trovan).
Urinary tract infections (norfloxacin, lomefloxacin, enoxacin, ofloxacin, ciprofloxacin, levofloxacin, gatifloxacin, trovafloxacin) Lower respiratory tract infections (lomefloxacin, ofloxacin, ciprofloxacin, trovafloxacin) Skin and skin-structure infections (ofloxacin, ciprofloxacin, levofloxacin, trovafloxacin) Urethral and cervical gonococcal infections (norfloxacin, enoxacin, ofloxacin, ciprofloxacin, gatifloxacin, trovafloxacin) Prostatitis (norfloxacin, ofloxacin, trovafloxacin) Acute sinusitis (ciprofloxacin, levofloxacin, gatifloxacin, moxifloxacin (Avelox), trovafloxacin) Acute exacerbations of chronic bronchitis (levofloxacin, sparfloxacin (Zagam), gatifloxacin, moxifloxacin, trovafloxacin) Community-acquired pneumonia (levofloxacin, sparfloxacin, gatifloxacin, moxifloxacin, trovafloxacin)
Side Effects
The fluoroquinolones as a class are generally well tolerated. Most adverse effects are mild in severity, self-limited, and rarely result in treatment discontinuation. However, they can have serious adverse effects. The first impression is the best impression. We have written this article on Bronchitis in such a way that the first impression you get will definitely make you want to read more about it!
The fluoroquinolones are a family of synthetic, broad-spectrum antibacterial agents with bactericidal activity. The parent of the group is nalidixic acid, discovered in 1962 by Lescher and colleagues. The first fluoroquinolones were widely used because they were the only orally administered agents available for the treatment of serious infections caused by gram-negative organisms, including Pseudomonas species. We have included the history of Chronic Bronchitis here so that you will learn more about its history. It is only through it's history can you learn more about Chronic Bronchitis.
Second Generation
The second-generation fluoroquinolones have increased gram-negative activity, as well as some gram-positive and atypical pathogen coverage. Compared with first-generation quinolones, these drugs have broader clinical applications in the treatment of complicated urinary tract infections and pyelonephritis, sexually transmitted diseases, selected pneumonias and skin infections. The facts on Chronic Bronchitis mentioned here have a consequential impact on your understanding on Chronic Bronchitis. This is because these facts are the basic and important points about Chronic Bronchitis.
Classification of Fluoroquinolones
As a group, the fluoroquinolones have excellent in vitro activity against a wide range of both gram-positive and gram-negative bacteria. The newest fluoroquinolones have enhanced activity against gram-positive bacteria with only a minimal decrease in activity against gram-negative bacteria. Their expanded gram-positive activity is especially important because it includes significant activity against Streptococcus pneumoniae. Don't be surprised if you find anything unusual here about Chronic Bronchitis. There has been some interesting and unusual things here worth reading. :D.
Fluoroquinolones advantages: Ease of administration Daily or twice daily dosing Excellent oral absorption Excellent tissue penetration Prolonged half-lives Significant entry into phagocytic cells Efficacy Overall safety
(https://s3-us-west-2.amazonaws.com/979/imgs/bronchitis-child0.jpeg)
How is Acute Bronchitis Treated the Treatment of Acute Bronchitis is
Fluoroquinolones disadvantages: Tendonitis or tendon rupture Multiple drug interactions Not used in children Newer quinolones produce additional toxicities to the heart that were not found with the older agents
Second-generation agents include ciprofloxacin, enoxacin, lomefloxacin, norfloxacin and ofloxacin. Ciprofloxacin is the most potent fluoroquinolone against P. aeruginosa. Ciprofloxacin and ofloxacin are the most widely used second-generation quinolones because of their availability in oral and intravenous formulations and their broad set of FDA-labeled indications. :o.
Conditions Treated With Fluoroquinolones: Indications and Uses
The newer fluoroquinolones have a wider clinical use and a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. Some of the newer fluoroquinolones have an important role in the treatment of community-acquired pneumonia and intra-abdominal infections. The serum elimination half-life of the fluoroquinolones range from 3 -20 hours, allowing for once or twice daily dosing. Having a penchant for Chronic Bronchitis led us to write all that there has been written on Chronic Bronchitin (http://osvaldobarnett.createaforum.com/bronchitis-natural-7/the-number-of-people-have-bronchitis-in-depth-info/) here. Hope you too develop a penchant for Chronic Bronchitis!
Because of their expanded antimicrobial spectrum, third-generation fluoroquinolones are useful in the treatment of community-acquired pneumonia, acute sinusitis and acute exacerbations of chronic bronchitis, which are their primary FDA-labeled indications. The third-generation fluoroquinolones include levofloxacin, gatifloxacin, moxifloxacin and sparfloxacin.
Third Generation
The third-generation fluoroquinolones are separated into a third class because of their expanded activity against gram-positive organisms, particularly penicillin-sensitive and penicillin-resistant S. pneumoniae, and atypical pathogens such as Mycoplasma pneumoniae and Chlamydia pneumoniae. Although the third-generation agents retain broad gram-negative coverage, they are less active than ciprofloxacin against Pseudomonas species.
The newer fluoroquinolones have a wider clinical use and a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. Some of the newer fluoroquinolones have an important role in the treatment of community-acquired pneumonia and intra-abdominal infections. There has been an uncalculatable amount of information added in this composition on Bronchitis. Don't try counting it!
Because of concern about hepatotoxicity, trovafloxacin therapy should be reserved for life- or limb-threatening infections requiring inpatient treatment (hospital or long-term care facility), and the drug should be taken for no longer than 14 days. We would like you to leisurely go through this article on Bronchitis to get the real impact of the article. Bronchitis is a topic that has to be read clearly to be understood.